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Background
Fibrosis is a common end-point in pathological pro-
cesses. It is unclear, however, if diffuse fibrosis occurs
early in the pathogenesis of hypertrophic cardiomyopa-
thy (HCM). The purpose of this study was to evaluate
the presence of diffuse myocardial fibrosis in children
and adolescents with HCM using quantification of T1
changes late after gadolinium administration and to
assess for associations between markers of fibrosis and
standard clinical parameters of disease.
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Figure 1 A single mid-ventricular slice is imaged over multiple inversion times. A curve-fitting technique is used to create a T1 map of the
myocardium. Individual regions of interest in the septum, blood pool and lateral wall are subsequently drawn and recorded.
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Methods
Patients with confirmed HCM and healthy controls parti-
cipated in this study. T1 measurements were made using
standard multi-breath-hold spoiled gradient echo phase-
sensitive inversion-recovery MRI. They were performed
before and 15 minutes after 0.2 mmol/kg gadopentetate
dimeglumine in a single mid-ventricular slice using
increasing inversion times per breath-hold (150, 400, 800
and 3200 ms). For analysis, regions of interest were
drawn in the septum, blood pool and left ventricular
(LV) lateral wall, avoiding myocardium showing overt
late enhancement (LGE). A curve-fitting technique was
used to derive the T1 time constant (Figure 1). The
tissue-blood partition coefficient (PCf) was calculated as
a function of the ratio of T1 change of myocardium com-
pared to blood [1]: higher PCf values indicate greater
fibrosis. Clinical data included LV mass, ejection fraction,
presence of LGE, symptoms, serum brain-natriuretic-
peptide (BNP), mitral valve inflow velocities and presence
of outflow tract obstruction at rest.
Results
12 controls (mean age 12.8yrs; 7 male) and 28 patients
(mean age 12.8yrs; 21 male) participated. All patients had
a clinical diagnosis of HCM. Among these, 20 children
had HCM-specific mutations. Clinical parameters are
given in table 1. PCf for both septal (0.27±0.17 vs. 0.13
±0.09 ml/g; p=0.03) and lateral walls (0.22±0.09 vs. 0.07
±0.10; p<0.001) were increased in patients compared to
controls. PCf did not correlate with age, either in patients
or normal individuals.
Eight patients had overt areas of LGE. These patients
did not show increased coefficients compared to those
without LGE (0.27±0.15 vs. 0.27±0.19 and 0.22±0.09 vs.
0.22±0.09; p=0.95 and 0.98 respectively). However,
patients that were symptomatic (dyspnoea, arrhythmia
or chest pain) had higher lateral wall coefficients than
asymptomatic HCM patients (0.27±0.08 vs. 0.17±0.08;
p=0.006). Similarly, patients with raised BNP (>100 pg/
ml) had raised lateral wall coefficients (0.27±0.07 vs.
0.20±0.07; p=0.03). Other clinical parameters did not
show any discrimination with respect to the lateral
coefficient.
Conclusions
Diffuse fibrosis, demonstrated by the partition coeffi-
cient technique, is demonstrable in children and adoles-
cents with HCM. Markers of fibrosis show an
association with symptoms and raised serum BNP.
Further study of the prognostic implication of this tech-
nique is warranted.
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No. male 7 21
Age (yrs.) 12.8 ± 2.2 12.8 ± 2.6 0.95
Septum partition
coefficient (ml/g)
0.13 ± 0.09 0.27 ± 0.17 0.03*
Lateral wall partition
coefficient (ml/g)
0.07 ± 0.10 0.22 ± 0.09 <0.001*
BNP (pg/ml) 10.1 ± 6.6 283 ± 429 0.009*
Number with LGE 0 8
Ejection fraction (%) 57 ± 3 68 ± 10 <0.001*
Indexed myocardial mass
(g/m2)
54 ± 7 103 ± 40 <0.001*
Note that the partition coefficients are significantly raised in HCM patients
compared with controls. (BNP = Brain Natriuretic Peptide; LGE = Late
Gadolinium Enhancement)
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